Annals of Hematology最新文献

{"title":"CDKN1A as a potential target for Eltrombopag treatment in ITP and its regulation of the communication between macrophages and transitional B cells in ITP.","authors":"Shixuan Wang, Mankai Ju, Fancong Kong, Yuhuan Jiang, Yechao Tu, Jingyun Zou, Zhiming Zou, Genmei Tan, Fei Li","doi":"10.1007/s00277-025-06436-5","DOIUrl":"10.1007/s00277-025-06436-5","url":null,"abstract":"<p><p>This study aimed to identify novel biomarkers associated with Eltrombopag response in patients with immune thrombocytopenia (ITP) and to investigate the role of macrophage and transitional B cells in ITP pathogenesis. Differentially expressed genes were identified using the GSE112278 dataset, followed by weighted gene co-expression network analysis (WGCNA) to screen hub genes. Single-cell RNA-seq data from GSE196676 were analyzed using the Seurat package to assess immune cell composition, gene expression, and cell-cell communication. CDKN1A expression was experimentally modulated in RAW264.7 macrophages via siRNA knockdown or plasmid overexpression. Phagocytic function was assessed using CFDA-labeled mouse platelets and F4/80 immunofluorescence staining. Molecular docking was conducted to evaluate the interaction between Eltrombopag and CDKN1A. Through intersection analysis, we identified CDKN1A as a key gene influencing the response of ITP patients to Eltrombopag treatment. Single-cell data analysis revealed a significant increase in the proportion of macrophages in ITP patients, accompanied by downregulation of CDKN1A expression in these macrophages, which was closely associated with macrophage activation and enhanced phagocytic capacity. Functional experiments confirmed that CDKN1A knockdown promoted, while overexpression inhibited, macrophage phagocytosis of platelets. Additionally, cell communication analysis demonstrated that macrophages in ITP patients interact with transitional B cells via the TGFβ signaling pathway. Further analysis revealed that a subset of macrophages performs effector functions by differentiating into specialized subtypes that function independently, without direct interaction with other immune cells. Our study identified CDKN1A as a key regulator of Eltrombopag's effectiveness in treating ITP. CDKN1A expression was reduced in macrophages of ITP patients and that it interacted with transitional B cells through the TGFβ signaling pathway to promote disease progression. These findings offer new insights into the pathogenic mechanisms of ITP and suggest CDKN1A as a potential therapeutic target for future interventions.</p>","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":" ","pages":"3183-3197"},"PeriodicalIF":3.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12283840/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144293241","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Latest updates on pathogenesis mechanisms and management strategies for cytokine release syndrome, neurotoxicity, and hemophagocytic lymphohistiocytosis related to CAR-T cell therapies.","authors":"Xin Wang, Xiaoyuan He, Tao Zhang, Jile Liu, Mingfeng Zhao","doi":"10.1007/s00277-025-06467-y","DOIUrl":"10.1007/s00277-025-06467-y","url":null,"abstract":"<p><p>Nowadays, chimeric antigen receptor (CAR) -T cell therapy has shown significant efficacy in treating hematological tumors, with an obvious increase in patient survival rates. However, with the widespread application of CAR-T, the incidence of CAR-T related adverse events has gradually increased, including cytokine release syndrome (CRS), immune effector cell associated neurotoxicity syndrome (ICANS), and hemophagocytic lymphohistiocytosis (HLH). These complications may be life-threatening, so early diagnosis and intervention treatment are crucial for the prognosis of patients. In this review, we first comprehensively summarize the latest insights into the pathogenesis and clinical manifestations of CRS, ICANS, and HLH after CAR-T, with a focus on elaborating on the specific mechanisms and related pathways of the inflammatory storm caused by a large number of cytokines after CAR-T. We also discussed the established prevention and management strategies for the three complications mentioned above, and demonstrated the effectiveness of the treatment by introducing the therapeutic effects of various treatment methods in current clinical or preclinical trials. In addition, we provide a prospective perspective on the measures and modifications currently being studied to mitigate the toxicity associated with CAR-T cell therapy.</p>","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":" ","pages":"3129-3151"},"PeriodicalIF":3.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12283850/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144324354","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment outcomes in elderly patients ≥ 65 years with Large B-Cell Lymphoma (LBCL): a real-world single center experience focusing on potential CD19-CAR-T eligibility in second line.","authors":"Elena Maiolo, Gabriele Schiaffini, Silvia Bellesi, Eleonora Alma, Flaminia Bellisario, Marcello Viscovo, Fabrizia Campana, Francesco D'Alò, Stefan Hohaus","doi":"10.1007/s00277-025-06478-9","DOIUrl":"10.1007/s00277-025-06478-9","url":null,"abstract":"<p><p>Elderly LBCL patients have unfavorable clinical and biological features, leading to higher relapse rates. While CD19 CAR-T therapy offers a curative option in second-line, access remains limited by clinical criteria in pts aged ≥ 65 years. In our real-world study, we evaluated 232 LBCL pts ≥ 65 years focusing on first line outcomes and potential CAR-T eligibility. Sixty-four patients progressed or relapsed. Applying AIFA criteria, only 9/37 (24%) R/R LBCL pts aged 65-75 years would have been CAR-T eligible. Among those > 75 years, excluded from CAR-T in Italy, only 3/27 (11%) met eligibility criteria. The main exclusion criteria were ECOG ≥ 2 (34 pts, 53%), CNS involvement (14 pts, 22%) and rapidly progressive disease with life expectancy < 12 weeks (12 pts, 19%) The majority of pts who would have been excluded from CAR-T therapy had multiple criteria (32/52, 61%). Pts not receiving full-dose anthracyclines would have been seldom candidates for CAR-T (only 2/12, 16.5%). This study provides an estimate of the potential eligibility to CAR-T cell therapy in an elderly population of R/R LBCL in a real world setting of a CAR-T center. These findings highlight the urgent need for improved first-line therapies for elderly R/R LBCL pts.</p>","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":" ","pages":"3333-3344"},"PeriodicalIF":3.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12283872/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144504742","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"New FDG-PET/CT interpretation criteria (Huaxi criteria) for response assessment in patients with nasal-type extranodal NK/T-cell lymphoma: development and validation.","authors":"Li Li, Futao Cui, Rong Tian, Ming Jiang, Liqun Zou, Xin Li, Minggang Su","doi":"10.1007/s00277-025-06420-z","DOIUrl":"10.1007/s00277-025-06420-z","url":null,"abstract":"<p><p>The Deauville criteria are recommended for PET/CT-based treatment response evaluation in extranodal NK/T-cell lymphoma (ENKTL) but have limited prognostic value. Therefore, we conducted a retrospective study of 340 nasal-type ENKTL patients to develop new criteria (Huaxi criteria) and validate them for assessing therapeutic response and survival outcome. 80% (140/175) of the patients who did not receive any anticancer therapy after the end-of-treatment PET/CT (EOT-PET/CT) and had a progression-free survival > 24 months were randomly selected as subjects for developing Huaxi criteria. On EOT-PET/CT, the SUV_max of initial and new lesions at each site (including the upper aerodigestive tract [UADT] and nodal and extranodal sites) and liver SUV_max were measured to calculate the lesion-to-liver ratio (LLR). The 99th percentile upper-reference limits of the LLRs of lesions at each site were used to divide the lesion response into complete metabolic response (CMR) and non-CMR/new tumor. The Huaxi criteria were then established using an LLR-based 3-point scoring system. Interreader agreement was assessed using kappa statistics. Kaplan‒Meier and Cox regression analyses were used to compare survival outcomes. The prognostic ability was assessed using the hazard ratio (HR), which was calculated via univariate Cox regression analysis. The results showed that the LLR thresholds for assessing CMR and non-CMR/new tumor at the UADT and nodal and extranodal sites were 2.0, 1.5 and 1.0, respectively. The Huaxi criteria were employed to score the lesions at each site using the LLR-based 3-point scale, with the highest score denoting the overall response. Scores 1 and 2 represent CMR, and score 3 represents non-CMR. Interreader agreement was substantial for the Huaxi criteria but only moderate-substantial for the Deauville criteria (κ, 0.663‒0.756 vs. 0.454‒0.711). The Huaxi criteria improved the positive predictive value (PPV) for prognosis from 21.9‒41.4% with the Deauville criteria to 53.4‒73.1%. The Huaxi criteria were an independent prognostic factor at EOT and interim (all P < 0.001), with better predictive performance than the Deauville criteria (HR, 5.25‒11.56 vs. 1.59‒3.66, all P < 0.05). In conclusion, the Huaxi criteria are concise, with substantial interreader agreement and a high PPV for prognosis, and can independently predict outcomes in nasal-type ENKTL patients.</p>","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":" ","pages":"3377-3387"},"PeriodicalIF":3.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12283479/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144207498","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The expression patterns and prognostic significance of PD-1 and TIM-3 on T cells and the differentiated subsets in acute myeloid leukemia.","authors":"Kai Sun, Zong-Yan Shi, Ya-Zhe Wang, Dai-Hong Xie, Yan-Rong Liu, Qian Jiang, Hao Jiang, Xiao-Jun Huang, Ya-Zhen Qin","doi":"10.1007/s00277-025-06418-7","DOIUrl":"10.1007/s00277-025-06418-7","url":null,"abstract":"<p><p>Researches on the immune checkpoint molecule and its clinical application in acute myeloid leukemia (AML) fall behind solid tumors. The expression patterns and prognostic significance of immune checkpoint molecules across T cells and T-cell differentiated subsets in AML require further elucidation. In the present study, bone marrow (BM) samples from 165 newly diagnosed AML patients and 12 healthy donors (HDs) were tested PD-1 and TIM-3 expression on CD4⁺ and CD8⁺T cells as well as their differentiated subsets by multi-parameter flow cytometry. Compared with HDs, PD-1 was significantly overexpressed on total CD4⁺T cells and their major constituent subsets (naïve, central memory, and effector memory T cells; all P < 0.05), whereas TIM-3 was overexpressed on both total CD4⁺ and CD8⁺T cells, as well as all differentiated subsets (all P < 0.05). Both high expressions of PD-1 on CD8⁺T and TIM-3 on CD4⁺T cells were associated with poor relapse-free survival (RFS) and event-free survival (EFS) (all P < 0.05). In addition, high PD-1 expression on CD8⁺T cells independently predicted poorer RFS and EFS (P = 0.010 and 0.0011). Further stratification by T-cell subsets revealed that high PD-1 expression on naïve CD4⁺T cells and TIM-3 on effector CD4⁺T cells emerged as independent adverse prognostic factors for RFS (P = 0.018 and P = 0.034, respectively), replacing the prognostic impact of PD-1 on total CD8⁺T cells. However, high PD-1 expression on CD8⁺T cells remained the sole independent predictor of EFS (P = 0.0065). In conclusion, the expression patterns of PD-1 and TIM-3 in the BM T cells and their differentiated sub-populations in newly diagnosed AML patients were distinct from HDs, and predicted outcomes.</p>","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":" ","pages":"3235-3250"},"PeriodicalIF":3.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12283477/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144149030","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Revealing silent alpha-thalassemia: characterization of novel HBA1 deletion and missense mutation in Tunisian families.","authors":"Yessine Amri, Sondess Hadj Fredj, Rym Dabboubi, Rym Othmani, Chaima Sahli, Imen Baccouche, Faida Ouali, Taieb Messaoud","doi":"10.1007/s00277-025-06320-2","DOIUrl":"10.1007/s00277-025-06320-2","url":null,"abstract":"<p><p>Alpha-thalassemia is a common inherited hemoglobin disorder caused by deletions or point mutations in the HBA1 and/or HBA2 genes, leading to reduced or absent synthesis of alpha-globin chains. Although deletional mutations are predominant, non-deletional mutations can also contribute to the clinical spectrum of the disease, with varying severity. This study aimed to characterize two novel mutations in the HBA1 gene, a 230 bp microdeletion and a missense mutation (NP_000549.1:p.Ala29Pro), identified in two unrelated Tunisian families. Additionally, we assessed the clinical, hematological, molecular, and in silico structural impact of these mutations. Peripheral blood samples were collected from affected individuals and family members. Hematological parameters were measured using automated cell counters, and hemoglobin fractions were analyzed by high-performance liquid chromatography (HPLC). Genomic DNA was extracted, and common α-thalassemia deletions were screened via gap-PCR. Negative cases underwent sequencing of HBA1 and HBA2 exons. The novel deletion was confirmed by gap-PCR, gel purification, and sequencing. The pathogenicity of the missense mutation was assessed using in silico tools (PolyPhen-2, SIFT, MutationTaster), and structural modeling was performed using Swiss-PdbViewer and DynaMut to evaluate protein stability and flexibility. In Family A, a 4-year-old proband exhibited mild anemia, microcytosis, hypochromia, and low ferritin levels unresponsive to iron supplementation. A novel heterozygous 230 bp deletion (NC_000016.10:g.176695_176925del), named Hemoglobin Ariana, was identified in the HBA1 gene, affecting the 5'UTR, exon 1, and part of intron 1. In Family B, a 4-month-old proband presented with co-inheritance of α-thalassemia and Hemoglobin C. Sequencing revealed a novel missense mutation (NM_000558.5:c.85G > C, NP_000549.1:p.Ala29Pro), designated Hemoglobin Tozeur. In silico analysis predicted the mutation as deleterious, with structural modeling indicating destabilization of the α-globin protein, reduced stability, and altered flexibility near the heme-binding region. This study identifies two novel HBA1 mutations associated with α-thalassemia in Tunisia. The combined clinical, molecular, and structural analyses highlight the importance of comprehensive genetic screening and in silico modeling for accurate diagnosis and improved management of thalassemia cases.</p>","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":" ","pages":"3173-3182"},"PeriodicalIF":3.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12283798/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144246110","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Down-regulation of circMUC16 inhibited the progression of ALL via interaction with miR-1182 and TPPP3.","authors":"Jianjun Tang, Jing Sun, Jianyun Liao, Chaoke Pu, Shanshan Yuan, Chongchong Li, Jiayin Chen, Lei Shang, Zekai Pan, Jiaqi Chen","doi":"10.1007/s00277-025-06354-6","DOIUrl":"10.1007/s00277-025-06354-6","url":null,"abstract":"<p><p>Circular RNA (circRNA) is crucial in various biological processes, particularly in the onset and progression of different diseases. Nevertheless, the function of circMUC16 in acute lymphoblastic leukemia (ALL) remains unclear. The expression of circMUC16, miR-1182 and TPPP3 was evaluated by qPCR. The role of circMUC16 in the progression of ALL was investigated bymcherry-EGFP-LC-3, cell cycle, flow cytometry apoptosis, caspase-3 activity, western blotting, and an in vivo xenograft model. The interactions among circMUC16, miR-1182, and TPPP3 were explored by using qPCR, western blot, dual-luciferase reporter, and RNA immunoprecipitation assays.In this study, it was found that circMUC16 was increased in ALL cells. Down-regulation of circMUC16 reduced autophagy, cell proliferation and increased apoptosis in vitro while inhibiting cancer in vivo. circMUC16 acted as a molecular sponge of miR-1182. The carcinogenic effect of circMUC16 was partially mediated by miR-409-3p. TPPP3 was shown to be a direct target of miR-1182 and to be competed with circMUC16. Overexpression of TPPP3 partially counteracted the inhibitory effects of sh-circMUC16 inhibition on malignant behaviors of ALL cells. This study revealed that the circMUC16/miR-1186/TPPP3 axis plays a crucial role in the progression of ALL, suggesting a novel therapeutic target for ALL therapy.</p>","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":" ","pages":"3389-3401"},"PeriodicalIF":3.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12283428/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144473887","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ruxolitinib treatment outcomes in acute graft-versus-host disease (aGvHD) in a real-world setting in Finland.","authors":"Eeva Martelin, Arttu Kuikka, Hanna Rajala, Tuomas Ruohonen, Hannu Mönkkönen, Johanna Vikkula, Kristiina Uusi-Rauva, Urpu Salmenniemi, Maija Itälä-Remes","doi":"10.1007/s00277-025-06439-2","DOIUrl":"10.1007/s00277-025-06439-2","url":null,"abstract":"","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":" ","pages":"3451-3458"},"PeriodicalIF":3.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12283849/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144232960","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epidemiologic trends for pediatric Hodgkin and non-Hodgkin lymphomas: a U.S. population-based study.","authors":"Weishi Cheng, Xu Sun, Shijie Yang, Kai Kang, Li Wang, Chang Han, Yijun Wu, Ailin Zhao, Ting Niu","doi":"10.1007/s00277-025-06445-4","DOIUrl":"10.1007/s00277-025-06445-4","url":null,"abstract":"<p><p>Pediatric Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) are distinct from adult forms and occur less frequently. We identified 7,871 children and 226,211 adults with lymphoma from the Surveillance, Epidemiology, and End Results database from 1975 to 2018. The age-adjusted incidence rate for pediatric lymphoma was 24.5 per million persons (95% CI: 24.0-25.1), comprising 13.0 per million (95% CI: 12.6-13.4) for HL and 11.5 per million (95% CI: 11.1-11.9) for NHL. In comparison to adult lymphoma, pediatric lymphoma showed no significant changes in incidence from 1975 to 2002 (annual percentage change, APC = -0.12 ± 0.19, P = 0.53), but displayed an observable increase after 2003 (APC = + 1.31 ± 0.45, P = 0.006). Among pediatric cases, the 5-year limited-duration prevalence rate increased from 0.00691% in 1996 to > 0.009% in recent years, and the 20-year rate rose from 0.0109% in 1996 to 0.0148% in 2018. In alignment with the observed decrease in incidence over the recent decade, the prevalence of adult lymphoma exhibited a more gradual growth post-2007. Among adult patients, the age-adjusted mortality rate demonstrated an initial increase in the periods 1975-1977 (APC = + 41.06 ± 6.23, P < 0.001), 1977-1980 (APC = + 9.83 ± 4.27, P = 0.036), 1980-1989 (APC = + 5.24 ± 0.36, P < 0.001), and 1989-1994 (APC = + 2.27 ± 0.86, P = 0.014), followed by a subsequent decrease after 1994 (APC= -0.49 ± 0.05, P < 0.001). In contrast, the mortality rates of pediatric lymphoma exhibited a consistent decrease over the past four decades (1975-2018: APC= -3.12 ± 0.29, P < 0.001), resulting in an overall age-adjusted mortality rate of 2.92 (95% CI: 2.73-3.11).</p>","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":" ","pages":"3299-3307"},"PeriodicalIF":3.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12283834/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144324353","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic factors of survival in second allogeneic hematopoietic transplantation.","authors":"Rodrigo Cantera Estefanía, Raquel García Ruiz, Sara Fernández-Luis, Juan José Domínguez-García, Tatiana Fernández Barge, Jon Salmanton-García, Irene Francés Alexandre, Ana Tobalina García, Ana Gea Peña, Irene Gorostidi Álvarez, María Oviedo Madrid, Julia Bannatyne Undabeitia, Leddy Patricia Vega Suárez, María Terán Díaz, Miriam Sánchez Escamilla, Mercedes Colorado Araujo, Mónica López Duarte, Lucrecia Yáñez San Segundo, Enrique M Ocio, Arancha Bermúdez Rodríguez","doi":"10.1007/s00277-025-06469-w","DOIUrl":"10.1007/s00277-025-06469-w","url":null,"abstract":"<p><p>Allogeneic stem cell transplantation (alloSCT) remains a potentially curative treatment for patients with hematologic malignancies. Nevertheless, relapse and graft failure continue to be major barriers to long-term success. In these high-risk situations, a second alloSCT may represent the only curative option, although outcomes are frequently compromised by high non-relapse mortality and disease progression. Despite improvements in conditioning regimens, donor availability, and supportive care strategies, clinical results remain suboptimal and underscore the importance of careful patient selection.In this study, we report the 15-year experience of our institution-a national reference center for alloSCT in Spain-in managing patients undergoing a second alloSCT. Our objective is to evaluate relevant clinical and transplant-related factors associated with survival outcomes. Ultimately, we aim to enhance the selection process and contribute to a more personalized approach to 2nd-alloSCT, helping clinicians make better-informed decisions about which patients are most likely to benefit from this high-risk but potentially life-saving procedure.</p>","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":" ","pages":"3447-3450"},"PeriodicalIF":3.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12283476/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144473890","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}